- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05423665
Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies (HEART)
Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth in Twin Pregnancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies.
In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Eline Meireson
- Phone Number: 0032 9 332 78 17
- Email: eline.meireson@uzgent.be
Study Locations
-
-
-
Ghent, Belgium, 9000
- Recruiting
- Ghent University Hospital
-
Contact:
- Kristien Roelens, prof. dr.
-
Leuven, Belgium, 3000
- Not yet recruiting
- Universitair Ziekenhuis Leuven
-
Contact:
- Liebeth Lewie, prof. dr.
-
-
-
-
-
Eindhoven, Netherlands, 5631
- Not yet recruiting
- Maxima Medical Center
-
Contact:
- Judith van Laar, dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
The number of subjects that will be included in this study is: 600 neonates (200 twin pairs and 200 singletons) and 400 pregnant mothers.
The fetuses are divided into following sub-groups:
- Appropriately grown
- Fetal growth restricted
- Selective fetal growth restricted (specific for twins)
Description
Inclusion Criteria:
- Singleton or dichorionic twin pregnancy
- Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit
- Women ≥ 18 years
Exclusion Criteria:
- Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy
- Fetal arrhythmia
- Known fetal congenital or genetic abnormalities
- Any suspicion of congenital fetal anomalies that might influence fetal cardiac function
- Pre-existing maternal hypertensive disease
- Autoimmune disease including systemic lupus erythematosus
- History of stillbirth
- Diabetes mellitus (mother)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Fetal growth restricted
Observation of cardiac remodeling perinatal and postnatal
|
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
|
|
Appropriately grown
Observation of cardiac remodeling perinatal and postnatal
|
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the change in strain measured by speckle tracking echocardiography as a tool for early diagnosis of impaired fetal growth in multiple gestations
Time Frame: Prenatal to 1-3 days after birth
|
to determine the change in fetal strain and strain rate in twin pregnancies in comparison with fetal growth
|
Prenatal to 1-3 days after birth
|
|
To determine the intra-pair differences in fetal growth and strain (cardiac remodeling) in multiple gestations.
Time Frame: Prenatal to 1-3 days after birth
|
to compare changes in strain and strain rate with fetal growth within 1 twin pair
|
Prenatal to 1-3 days after birth
|
|
To compare the strain values (cardiac remodeling) between singletons and twin pregnancies
Time Frame: Prenatal to 1-3 days after birth
|
to compare the changes in strain and strain rate between singletons and twin pregnancies
|
Prenatal to 1-3 days after birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To investigate the association between placenta functioning and in utero cardiac remodeling
Time Frame: Prenatal to 1-3 days after birth
|
to evaluate placenta insufficiency (Doppler ultrasound, biochemical marker) with strain and strain rate
|
Prenatal to 1-3 days after birth
|
|
To explore in utero cardiac remodeling in association with neonatal cardiovascular health
Time Frame: Prenatal to 1-3 days after birth
|
to evaluate strain and strain rate with the neonatale blood pressure and heart rate
|
Prenatal to 1-3 days after birth
|
|
To study the association between prenatal air pollution exposure and in utero cardiac remodeling
Time Frame: Prenatal to 1-3 days after birth
|
to evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with strain and strain rate
|
Prenatal to 1-3 days after birth
|
|
To investigate placenta functioning as a mediator between air pollution and cardiac remodeling
Time Frame: Prenatal to 1-3 days after birth
|
To evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with placenta insufficiency (biochemical marker, Doppler ultrasound)
|
Prenatal to 1-3 days after birth
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kristien Roelens, University Hospital, Ghent
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONZ-2022-0193
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Air Pollution
-
U.S. EPA Human Studies FacilityRecruitingAir PollutionUnited States
-
UConn HealthNational Institute of Environmental Health Sciences (NIEHS)Completed
-
C-Polar InnovationsKelowna General HospitalNot yet recruiting
-
University Hospitals Cleveland Medical CenterPeking University; University of MichiganCompletedAir PollutionUnited States, China
-
Alaska Native Tribal Health ConsortiumRecruitingAir Pollution, IndoorUnited States
-
Stanford UniversityDuke University; National Institute of Environmental Health Sciences (NIEHS)CompletedPregnancy | Air PollutionUnited States
-
University of LouisvilleNational Institute of Environmental Health Sciences (NIEHS)Completed
-
Environmental Protection Agency (EPA)Enrolling by invitationAir Pollution | Pollution; Exposure | Nutrition, HealthyUnited States
-
Rutgers, The State University of New JerseyNational Institute of Environmental Health Sciences (NIEHS)Completed
-
University of MichiganCompletedAir PollutionUnited States
Clinical Trials on sample collection
-
Institut PasteurCentre Médical de l'Institut PasteurRecruiting
-
Emory UniversityMichael J. Fox Foundation for Parkinson's ResearchCompletedDefining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative ProcessesParkinson's DiseaseUnited States
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Leukemia | Chemotherapy-Induced Gut Barrier DamageUnited States
-
Institut PasteurRecruiting
-
Poitiers University HospitalRecruitingPsoriasis | Psoriatic ArthritisFrance
-
Thomas Jefferson UniversityRecruitingBreast Cancer | Invasive Breast Cancer | Carcinoma in Situ of the BreastUnited States
-
The Wellcome Sanger InstituteCambridge University Hospitals NHS Foundation Trust; Hull University Teaching...Enrolling by invitation
-
UNICANCERRecruitingAdvanced Breast Cancer | Advanced Gastric Cancer | Advanced Urothelial Cancer | Advanced Non Small Cell Lung Cancer (NSCLC)France
-
Institut PasteurBiogroup Laboratoire de biologie médicaleRecruiting